Купить (150 RUB)
сгенерировать QR код
Открытый доступ
Доступ платный или только для Подписчиков
Внезапная сердечная смерть при гипертрофической кардиомиопатии у детей: подходы к профилактике
https://doi.org/10.21508/1027-4065-2024-69-3-6-18
Аннотация
Гипертрофическая кардиомиопатия — основная причина внезапной сердечной смерти у детей и подростков, которая в большинстве случаев обусловлена жизнеугрожающими аритмиями. В статье описаны факторы риска внезапной смерти и освещены основные проблемы профилактики внезапной сердечной смерти у детей с гипертрофической кардиомиопатией. Рассмотрены современные проблемы стратификации риска внезапной сердечной смерти у детей, основанные на оценке факторов риска и многофакторных математических моделях риска. Рассмотрены клинические, функциональные и генетические маркеры риска внезапной смерти у детей в сравнении со взрослой популяцией. Представлены показания к имплантации кардиовертера-дефибриллятора (ИКД) для профилактики внезапной смерти и оценена эффективность ИКД-терапии.
Об авторе
И. В. Леонтьева
ОСП «Научно-исследовательский клинический институт педиатрии и детской хирургии им. академика Ю.Е. Вельтищева» (Институт Вельтищева) ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Россия
Россия
Леонтьева Ирина Викторовна — д.м.н., проф.,
гл. науч. сотр. отдела детской кардиологии и аритмологии; проф. кафедры инновационной педиатрии и детской хирургии
125412 Москва, ул. Талдомская, д. 2
Список литературы
1. Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P. еt al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35(39): 2733–2779. DOI: 10.1093/eurheartj/ehu284
2. Ommen S.R., Mital S., Burke M.A., Day S.M., Deswal A., Elliott P. et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2020; 76: e159–e240. DOI: 10.1016/j.jacc.020.08.045
3. Arbelo E., Protonotarios A., Gimeno J.R., Arbustini E., Barriales-Villa R., Basso C. et al. ESC Scientific Document Group2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44(37): 3503–3626. DOI: 10.1093/eurheartj/ehad194
4. Maron B., Rowin E., Casey S., Lesser J., Garberich R., McGriff D.M. et al. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Circulation 2016; 133(1): 62–73. DOI: 10.1161/CIRCULATIONAHA.115.017633
5. Norrish G., Field E., Mcleod K., Ilina M., Stuart G., Bhole V. et al. Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom. Eur Heart J 2019; 40: 986–993. DOI: 10.1093/eurheartj/ehy798.
6. Marston N. A., Han L., Olivotto I., Day S. M., Ashley E. A., Michels M. et al. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J 2021; 42: 1988–1996. DOI: 10.1093/eurheartj/ehab14
7. Kaski J. P., Kammeraad J. A. E., Blom N. A., Happonen J. M., Janousek J., Klaassen S. et al. Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy: A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology. Cardiol Young 2023; 33(5): 681–698. DOI: 10.1017/S1047951123000872
8. Norrish G., Cleary A., Field E., Cervi E., Boleti O., Ziółkowska L. et al. Clinical features and natural history of pread olescent non-syndromic hypertrophic cardiomyopathy. J Am CollCardiol 2022; 79: 1986–1997. DOI: 10.1016/j.jacc.2022.03.347
9. Norrish G., Cantarutti N., Pissaridou E., Ridout D, Limongell G., Elliott P. et al. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. Eur J Prev Cardiol 2017; 24(11): 1220–1230. DOI: 10.1177/2047487317702519
10. Ostman-Smith I., Wettrell G., Keeton B., Holmgren D, Ergander U., Gould S. et al. Age-and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur Heart J 2008; 29(9): 1160–1167. DOI: 10.1093/eurheartj/ehn122
11. Miron A., Lafreniere-Roula M., Steve Fan C. P., Armstrong K. R., Dragulescu A., Papaz T. et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 2020; 142: 217–229. DOI: 10.1161/CIRCULATIONAHA.120.047235
12. Norrish G., Ding T., Field E., Ziólkowska L., Olivotto I., Limongelli G. et al. Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM risk-kids). JAMA Cardiol 2019; 4: 918–927. DOI: 10.1001/jamacardio.2019.2861
13. Maurizi N., Passantino S., Spaziani G., Girolami F., Arretini A., Targetti M. et al. Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors forlethal arrhythmic events. JAMA Cardiol 2018; 3: 520–525. DOI: 10.1001/jamacardio.2018.0789
14. Pettersen M.D., Du W., Skeens M.E., Humes, R.A. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 2008; 21(8): 922–934. DOI: 10.1016/j.echo.2008.02.006
15. Lopez L., Frommelt P.C., Colan S.D., Trachtenberg F.L., Gongwer R., Stylianou M. et al. Pediatric Heart Network Echocardiographic Z Scores: Comparison with Other Published Models. J Am Soc Echocardiogr 2021; 34(2): 185–192. DOI: 10.1016/j.echo.2020.09.019
16. Norrish G., Ding T., Field E., Cervi E., Ziółkowska L., Olivotto I. et al. Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol 2022; 15(5): e010075. DOI: 10.1161/CIRCEP.121.010075
17. Ziolkowska L., Turska-Kmiec A., Petryka J., Kawalec W. Predictors of long-term outcome in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2016; 37: 448–458. DOI: 10.1007/s00246–015–1298-y
18. Balaji S., DiLorenzo M.P., Fish F.A., Etheridge S.P., Aziz P.F., Russell M.W. et al. Risk factors for lethal arrhythmicvents in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study. Heart Rhythm 2019; 16: 1462–1467. DOI: 10.1016/j.hrthm.2019.04.040
19. Ostman-Smith I., Sjoberg G., Rydberg A., Larsson P., Fernlund E. Predictors of risk for sudden death in childhood hypertrophic cardiomyopathy: the importance of the ECG risk score. Open Heart 2017; 4(2): e000658. Published 2017 Oct 21. DOI: 10.1136/openhrt-2017–000658
20. Monserrat L., Elliott P.M., Gimeno J.R., Sharma S., PenasLado M., McKenna W.J. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42(5): 873–879. DOI: 10.1016/s0735-1097(03)00827-1
21. Norrish G., Chubb H., Field E., McLeod K., Ilina M., Spentzou G. et al. Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: a UK National Cohort Study. Europace 2021; 23(3): 400–408. DOI: 10.1093/europace/euaa307
22. Fancia P., Santini D., Musumeci B., Semprini L., Adduci C., Pagannone E. et al. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2014; 25(11): 1180–1187. DOI: 10.1111/jce.12492
23. Wang W., Lian Z., Rowin E.J., Maron B.J., Maron M.S., Link M.S. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol 2017; 10(3): e004604. DOI: 10.1161/CIRCEP.116.004604
24. Yang W.I., Shim C.Y., Kim Y.J., Kim S.A., Rhee S.J., Choi E.Y. et al. Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009; 22(12): 1338–1343. DOI: 10.1016/j.echo.2009.09.016
25. Maskatia S.A., Decker J.A., Spinner J.A., Kim J.J., Price J.F., Jefferies J.L. et al. Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2012; 33: 141–149. DOI: 10.1007/ s00246-011-0106-6
26. Nguyen M.B., Venet M., Fan C.S., Dragulescu A., Rusin C.G., Mertens L.L. et al. Modeling the Relationship Between Diastolic Phenotype and Outcomes in Pediatric Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr 2023: S0894-7317(23)00653-3. Online ahead of print DOI: 10.1016/j.echo.2023.11.025
27. Topriceanu C.C., Field E., Boleti O., Cervi E., Kaski J.P., Norrish G. Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy. Int J Cardiol 2023; 371: 523–525. DOI: 10.1016/j.ijcard.2022.09.044
28. Assaad I., Gauvreau K., Rizwan R., Margossian R., Colan S., Chen M.H. Value of Exercise Stress Echocardiography in Children with Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr 2020; 33(7): 888–894.e2. DOI: 10.1016/j.echo.2020.01.020
29. Xia K., Sun D., Wang R., Zhang Y. Factors associated with the risk of cardiac death in children with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart Lung 2022; 52: 26–36. DOI: 10.1016/j.hrtlng.2021.11.006
30. Östman-Smith I., Sjöberg G., Alenius Dahlqvist J., Larsson P., Fernlund E. Sudden cardiac death in childhood hypertrophic cardiomyopathy is best predicted by a combination of electrocardiogram risk-score and HCMRisk-Kids score. Acta Paediatr 2021; 110(11): 3105–3115. DOI: 10.1111/apa.16045
31. Bonura E.D., Bos J.M., Abdelsalam M.A., Araoz P.A., Ommen S.R., Ackerman M.J. et al. Cardiac Magnetic Resonance Imaging Features in Hypertrophic Cardiomyopathy Diagnosed at <21 Years of Age. Am J Cardiol 2020; 125(8): 1249–1255. DOI: 10.1016/j.amjcard.2020.01.027
32. Ali L.A., Marrone C., Martins D.S., Khraiche D., Festa P., Martini N. et al. Prognostic factors in hypertrophic cardiomyopathy in children: An MRI based study. Int J Cardiol 2022; 364: 141–147. DOI: 10.1016/j.ijcard.2022.06.043
33. Petryka-Mazurkiewicz J., Ziolkowska L., Kowalczyk-Domagala M., Mazurkiewicz L., Boruc A., Spiewak M. et al. LGE for Risk Stratification in Primary Prevention in Children With HCM. JACC Cardiovasc Imag. 2020; 13(12): 2684–2686. DOI: 10.1016/j.jcmg.2020.06.009
34. Sedaghat-Hamedani F., Kayvanpour E., Tugrul O.F., Lai A., Amr A., Haas J. et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol 2018; 107(1): 30–41. DOI: 10.1007/s00392-017-1155-5
35. Norrish G., Ding T., Field E., McLeod K., Ilina M., Stuart G. et al. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy. Europace 2019; 21(10): 1559–1565. DOI: 10.1093/europace/euz118
36. Norrish G., Qu C., Field E., Cervi E., Khraiche D., Klaassen S. et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol 2022; 29(4): 678–686. DOI: 10.1093/eurjpc/zwab181
37. Norrish G., Protonotarios A., Stec M., Boleti O., Field E., Cervi E. Performance of the PRIMaCY sudden death risk prediction model for childhood hypertrophic cardiomyopathy: implications for implantable cardioverter-defibrillator decision-making. Europace 2023; 25(11): euad330. DOI: 10.1093/europace/euad330
38. Kamp A.N., Von Bergen N.H., Henrikson C.A., Makhoul M., Saarel E.V., Lapage M.J. et al. Implanted defibrillatorsin young hypertrophic cardiomyopathy patients: a multicenter study. Pediatr Cardiol 2013; 34: 1620–1627. DOI: 10.1007/s00246-013-0676-6
39. Krause U., Müller M.J., Wilberg Y., Pietzka M., Backhoff D., Ruschewski W. et al. Transvenous and non-transvenous implantable cardioverter-defibrillators in children, adolescents, and adults with congenital heart disease: who is at risk for appropriate and inappropriate shocks? Europace 2019; 21(1): 106–113. DOI: 10.1093/europace/euy219
Рецензия
Для цитирования:
Леонтьева И.В. Внезапная сердечная смерть при гипертрофической кардиомиопатии у детей: подходы к профилактике. Российский вестник перинатологии и педиатрии. 2024;69(3):6-18. https://doi.org/10.21508/1027-4065-2024-69-3-6-18
For citation:
Leontyeva I.V. Sudden cardiac death in children with hypertrophic cardiomyopathy: approaches to prevention. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2024;69(3):6-18. (In Russ.) https://doi.org/10.21508/1027-4065-2024-69-3-6-18
Просмотров:
723
Послать статью по эл. почте 